Compare Ascendis Pharma A/S (ASND) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Teucrium Wheat Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Teucrium Wheat Fund trades at $23.85. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| ASND | WEAT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $25.49 |
52-Week Low | $163.32 | $19.88 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
WEAT trades at $23.72, up 2.91% today, with a bullish technical signal from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, and recent news highlights wheat price volatility and USDA production cuts affecting the agriculture sector. Support and resistance levels are tightly clustered around $23.
Outlook is influenced by commodity price swings and inflation trends, offering potential gains from wheat price increases but facing risks from supply adjustments and macroeconomic pressures. Investors should weigh sector-specific catalysts against inherent volatility in agricultural commodities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
